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Simple Summary: Breast cancer incidence not only increases with advancing age but also changes its
biology. This study was conducted to understand aging related change in the biological characteristics
of breast cancer. The results highlighted that the change occurs in a gradual fashion, where 40 years
and 70 years become the milestones for significant difference. Breast cancer in patients <40 years
showed aggressive characteristics while at 70 years and above they are more indolent. The molecular
pattern between 40 years and 70 years appears to be a transition from aggressive to less aggressive
phenotypes. This change in the biology of the breast cancer significantly influences clinical outcome.
Abstract: As age advances, breast cancer (BC) tends to change its biological characteristics. This
study aimed to explore the natural progression of such changes. The study included 2383 women
with clinically T0-2N0-1M0 BC, managed by primary surgery and optimal adjuvant therapy in a
dedicated BC facility. Tissue micro-arrays were constructed from their surgical specimens and indirect
immunohistochemistry was used for analysis of a large panel (n = 16) of relevant biomarkers. There
were significant changes in the pattern of expression of biomarkers related to luminal (oestrogen
receptor (ER), progesterone receptors (PgR), human epidermal growth factor receptor (HER-2), E-
cadherin, MUC1, bcl2 CK7/8, CK18 and bcl2) and basal (CK5/6, CK14, p53 and Ki67) phenotypes,
lymph node stage, histological grade and pathological size when decade-wise comparison was made
(p < 0.05). The ages of 40 years and 70 years appeared to be the milestones marking a change of
the pattern. There were significantly higher metastasis free and breast cancer specific survival rates
among older women with ER positive tumours while there was no significant difference in the ER
negative group according to age. Biological characteristics of BC show a pattern of change with
advancing age, where 40 years and 70 years appear as important milestones. The pattern suggests
<40 years as the phase with aggressive phenotypes, >70 years as the less aggressive phase and
40–70 years being the transitional phase.
Keywords: biology; breast cancer; older women
1. Introduction
Breast cancer is the most common malignancy among females, and the leading cause
of death worldwide [1]. With advancing age, not only does the incidence of breast cancer
rise, but also there appears to be a change in the biological characteristics. Starting from the
basic morphological features, older women tend to have a relatively higher rate of lobular
carcinoma, and a lower rate of more aggressive types like medullary carcinoma [2–4]. Older
women tend to have more grade I and II tumours as compared to the younger population
where they are more likely to have grade III tumours [3,5,6]. According to the existing
evidence, ER expression rises and the expression of HER2 and Ki67 declines with advancing
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age [2,7]. Therefore, it is generally accepted that older women tend to have less aggressive
tumours when compared to their younger counterparts [2,5]. It is debatable that aging
directly causes these differences, nevertheless a whole spectrum of biological alterations are
likely to occur, which in turn results in a change in the clinical behaviour of the cancer [8].
However, there is limited information available to understand the natural progression of
the pattern of biological characteristics with age. One method which could potentially tease
out the pattern is the analysis of expression of biomarkers across different age extremes.
To date however this has only been attempted in very few studies [9,10], and they tend to
include a small number of markers (i.e., mainly including conventional markers such as
oestrogen receptor (ER), progesterone receptors (PgR), human epidermal growth factor
receptor (HER-2), Ki67 and bcl2, which might not be sufficient to delineate any patterns.
Furthermore, the data were mostly collected retrospectively from multiple centres using
different laboratory methodologies further limiting their potential significance.
This study therefore took a stepwise approach and aimed to:
1. Explore the natural progression, if any, of the change in the biological characteristics
according to age as a whole. Given that the ER positive and ER negative phenotypes
show completely distinct clinical behaviours, their biological characteristics were also
compared and assessed according to age.
2. Compare clinical outcomes of the patients in different age groups, if significant
changes in their biological characteristics were found.
3. Compare the treatment patterns, if significant differences in clinical outcome were found.
2. Results
There were 2383 patients including: younger Nottingham Tenovus series—(n = 1808,
age range 18–70 years), and Elderly Primary Breast cancer series—(n = 575, age range
70–91 years). They were divided in decade wise fashion as follows: ≤30 (n = 19), 31–40
(n = 144), 41–50 (n = 496), 51–60 (n = 599), 61–70 (n = 551), 71–80 (n = 484) and ≥81 (n = 90).
2.1. Biological Features
2.1.1. Overall Pattern of Biomarkers
There were significant “step changes” according to age in the pattern of positivity of
ER (p < 0.001), PgR (p = 0.003), HER4 (p < 0.001), E-cadherin (p < 0.001), Ki67 (p < 0.001),
p53 (p = 0.003), CK5/6 (p < 0.001), CK7/8 (p = 0.006), CK14 (p < 0.001), CK17 (p < 0.03),
CK18 (p < 0.001) and bcl2 (p < 0.001). The ages of 40 years and 70 years were shown to
be the significant milestones when these “step changes” occurred (Table 1). Lymph node
stage (p = 0.01), pathological size of tumour (p < 0.001) and histological grade (p < 0.001)
also showed a significant pattern of change according to age (Table 1).


















1 7(50) 62 (50.8) 281 (62.0) 378 (64.1) 395 (68.6) 192 (57.1) 38 (57.6)
0.012 4 (28.6) 44 (36.1) 133 (29.4) 168 (28.5) 133 (23.1) 106 (31.5) 21 (31.8)
3 3 (21.4) 16 (13.1) 39 (8.6) 44 (7.5) 48 (8.3) 38 (11.3) 7 (10.6)
Histological Grade
1 0 5 (4.1) 83 (18.3) 131 (22.2) 110 (19.0) 51 (12.1) 13 (12.9)
<0.0012 2 (14.3) 25 (20.5) 140 (30.9) 200 (34.0) 209 (36.1) 166 (39.2) 46 (45.5)
3 12 (85.7) 92 (75.4) 230 (50.8) 258 (43.8) 260 (44.9) 206 (48.7) 42 (41.6)



















0.1–3.0 cm 9 (64.3) 100 (82.0) 402 (88.9) 533 (90.5) 537 (92.7) 377 (80.2) 87 (77.0)
<0.0013.1–5.0 cm 3 (21.4) 16 (13.1) 41 (9.1) 45 (7.6) 40 (6.9) 84 (17.9) 19 (16.8)
>5.0 cm 2 (14.3) 6 (4.9) 9 (2.0) 11 (1.9) 2 (0.3) 9 (1.9) 7 (6.2)
ER positive
(n = 2333) 8 (57.1) 57 (46.7) 314 (69.3) 436 (73.8) 470 (81.0) 322 (70.3) 79 (69.3) <0.001
PgR
(n = 2278) 7 (50.0) 51 (42.5) 281 (63.7) 339 (59.4) 327 (58.3) 255 (55.9) 62 (53.9) 0.003
HER2
(n = 2297) 0 16 (13.3) 37 (8.5) 50 (8.7) 37 (6.5) 37 (7.9) 8 (7.0) 0.232
Ki67
(n = 2020) 12 (85.7) 84 (89.4) 239 (63.7) 255 (53.5) 251 (56.2) 183 (37.3) 34 (27.9) <0.001
P53
(n = 2267) 3 (21.4) 53 (44.2) 133 (30.2) 152 (26.6) 127 (22.6) 156 (34.8) 43 (39.1) <0.001
Bcl2
(n = 1221) 0 28 (49.1) 73 (40.1) 110 (48.9) 90 (40.5) 345 (81.6) 96 (87.3) <0.001
Muc1
(n = 1962) 10 (83.3) 86 (82.7) 330 (89.7) 413 (89.6) 419 (90.7) 409 (91.5) 101 (93.5) 0.133
BRCA1
(n = 1979) 11 (84.6) 83 (80.6) 313 (82.8) 393 (83.4) 403 (86.1) 152 (34.5) 36 (34.3) <0.001
CK5/6
(n = 2274) 2 (14.3) 30 (25.0) 82 (18.4) 105 (18.4) 69 (12.1) 146 (32.7) 48 (44.4) <0.001
CK7/8
(n = 2296) 13 (92.6) 119 (99.2) 441 (98.9) 573 (99.0) 571 (99.7) 440 (97.1) 108 (97.3) 0.006
CK14
(n = 2193) 2 (14.3) 17 (14.2) 64 (14.4) 84 (14.7) 51 (9.1) 91 (23.6) 25 (24.5) <0.001
CK17
(n = 1160) 2 (66.7) 8 (22.2) 24 (15.1) 32 (10.7) 80 (18.6) 17 (15.5) 186 (16.0) 0.035
CK18
(n = 2176) 10 (71.4) 91 (76.5) 361 (86.4) 490 (91.4) 501 (93.1) 417 (95.2) 110 (97.3) <0.001
CK19
(n = 2292) 12 (85.7) 111 (92.5) 425 (95.3) 547 (94.3) 538 (94.6) 424 (94.0) 109 (97.3) 0.481
E-Cadherin
(n = 2289) 12 (85.7) 115 (95.0) 374 (84.6) 488 (84.7) 469 (82.9) 344 (74.9) 77 (69.4) <0.001
The overall age stratified expression of biomarkers showed four patterns (Figure 1):
4. A gradual rise starting at 40 years—ER, PgR, MUC1 and CK18.
5. A gradual decline starting at 40 years—Ki67, HER2, CK17 and E-cadherin.
6. A rise at 70 years—bcl2, CK5/6 and CK14.
7. Two peaks—CK7/8, CK19 and p53 (i.e., peak at 40 years then decline, rising again at
70 years).
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Figure 1. (A) Pattern of the expression of biomarkers with age stratification in early operable primary breast cancer treated
by surgery—significant rise at 40 years. (B) Pattern of the expression of biomarkers with age stratification in early operable
primary breast cancer treated by surgery—significant rise at 40 years (at nanozoomer magnification ×20). (C) Pattern of the
expression of biomarkers with age stratification in early operable primary breast cancer treated by surgery—significant
decline at 40 years. (D) Pattern of the expression of biomarkers with age stratification in early operable primary breast
cancer treated by surgery—significant decline at 40 years (at nanozoomer magnification ×20). (E) Pattern of the expression
of biomarkers with age stratification in early operable primary breast cancer treated by surgery—significant rise at 70 years.
(F) Pattern of the expression of biomarkers with age stratification in early operable primary breast cancer treated by
surgery—significant rise at 70 years (at nanozoomer magnification ×20). (G) Pattern of the expression of biomarkers with
age stratification in early operable primary breast cancer treated by surgery—two peaks. (H) Pattern of the expression of
biomarkers with age stratification in early operable primary breast cancer treated by surgery—two peaks (at nanozoomer
magnification ×20).
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Based on these patterns, the patients could be categorized into three distinct age
groups i.e., <40, 41–69 and ≥70 years. Immunohistochemical expression is presented in
Figure 1 for key patterns.
2.1.2. Pattern of Biomarkers According to ER Status
ER Positive Group
The following pattern was observed within the ER positive group (Figure 2):
Figure 2. Cont.
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Figure 2. (A) Pattern of the expression of biomarkers with age stratification in ER positive early operable primary breast
cancer treated by surgery—decline at 40 years. (B) Pattern of the expression of biomarkers with age stratification in
ER positive early operable primary breast cancer treated by surgery—rise at 70 years. (C) Pattern of the expression of
biomarkers with age stratification in ER positive early operable primary breast cancer treated by surgery—consistent decline.
(D) Pattern of the expression of biomarkers with age stratification in ER positive early operable primary breast cancer
treated by surgery—two peaks.
a. A rise at 40 years—HER2
b. A rise at 70 years—bcl2, CK5/6, CK14
c. Decline with advancing age—Ki67, E-cadherin
d. Two peaks—p53 and PgR (at 40 and 70 years)
However, MUC1, CK18, CK7/8 and CK19 remained unchanged throughout (more
than 80% of tumours were positive).
e. ER negative group
The following pattern was observed within the ER negative group (Figure 3).
Figure 3. Cont.








Figure 3. (A) Pattern of the expression of biomarkers with age stratification in ER negative early operable primary breast 
cancer treated by surgery—gradual rise. (B) Pattern of the expression of biomarkers with age stratification in ER negative 
early operable primary breast cancer treated by surgery—rise at 70 years. (C) Pattern of the expression of biomarkers with 
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Figure 3. (A) Pattern of the expression of bio arkers ith age stratification in ER negative early operable primary breast
cancer treated by surgery—gradual rise. (B) Pattern of the expression of biomarkers with age stratification in ER negative
early operable primary breast cancer treated by surgery—rise at 70 years. (C) Pattern of the expression of biomarkers with
age stratification in ER negative early operable primary breast cancer treated by surgery—decline at 70. (D) Pattern of the
expression of biomarkers with age stratification in ER negative early operable primary breast cancer treated by surgery—
two peaks.
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a. A rise at 40 years—MUC1 and CK18
b. A rise at 70 years—CK14
c. Rise at 30 years then decline at 70 years—HER2
d. Two peaks—Bcl2, CK5/6, Ki67, CK7/8, E-cadherin, p53 and CK17 (at 40 and 70 years).
However, PgR remained unchanged within the ER negative group (i.e., 93.9% negative).
2.2. Clinical Outcome
Breast Cancer Specific and Metastasis Free Survival Rates
Older women showed significantly higher 5-year Breast Cancer Specific Survival
(BCSS) (≤40 years = 75%, 41–69 years = 86%, ≥70 years = 90%, p-value 0.04, Figure S1).
While comparing patients with ER negative and ER positive tumours in the same age
groups, those with ER positive tumours showed significantly higher BCSS compared to
those with ER negative tumours in the 41–70 and >70 years age groups. However, when
just those with ER positive tumours were investigated in different age groups, older women
had significantly higher BCSS, as compared to their younger counterparts (Figure S1).
Metastasis free survival was also significantly higher among older women with ER
positive tumours (p = 0.03) as compared to younger age groups. Among patients with ER
negative tumours across all age groups, BCSS and metastasis free survival both remained
non-significant (Table 2).
Table 2. Clinical outcome of early operable primary breast cancer—comparison among age groups
based on oestrogen receptor status.
Outcome Measure ≤40 Years 41–70 Years ≥70 years p-Value
5-year Metastases free survival (%)
ER positive 68 85 87 0.003
ER negative 68 70 71 0.81
5-year Breast cancer specific survival (%)
ER positive 85 89 94 0.03
ER negative 70 73 75 0.88
2.3. Treatment Pattern
Most of the younger patients received more “aggressive” treatment including ad-
juvant chemotherapy and radiotherapy while a considerable number of older women
received surgery without adjuvant chemotherapy. Adjuvant endocrine therapy was used
considerably more frequently among older women with ER positive tumours, as compared
to younger patients (<40 years = 32%, 41–70 years = 41%, ≥70 years = 64%) A summary of
the treatment pattern is given in Table 3.
Table 3. Pattern of treatment of early operable primary breast cancer—comparison among age groups











ER negative age groups n (%)
≤40 5 (6.7) 61 (81.3) 0 9 (12.0)
41–70 59 (16.3) 124 (34.3) 108 (29.8) 71 (19.6)
>70 122 (72.2) 0 18 (10.7) 29 (17.2)
ER positive age groups n (%)
≤40 14 (1) 29 (36.7) 17 (21.5) 19 (24.1)
41–70 326 (28.5) 94 (8.2) 463 (40.5) 260 (22.7)
>70 116 (29.1) 2 (0.5) 257 (64.4) 24 (6.0)
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3. Discussion
The results of the study suggest that the biology of breast cancer alters in a gradual
fashion in relation to the age at the time of diagnosis. From the age stratified pattern, three
biological groups were identified, ≤40, 41–70 and >70 years of age. The pattern persisted
in both the ER positive and negative subgroups.
Tissue aging carries a high risk of cancer development due to a number of factors; for
instance, the long-term endogenous oestrogen exposure, reduction in the DNA repairing
ability of cells (high rate of p53 mutation), and a reduction in immunity with advancing
age may contribute to the process of carcinogenesis [10–13]. However, it is not yet fully
understood how advancing age produces such change in the biological characteristics of
the tumours.
In our study, the biological characteristics of breast cancer appeared to show a pattern
of alteration with increasing age, as a whole group and also when they were subdivided
into ER positive and negative subgroups. The ER expression itself showed a rise with
advancing age, which is in keeping with the available literature [2,9,10,14]. However, its
slight decline at 70 years in this series could be due to natural selection of relatively more
ER negative tumours for surgery, as the study was based on biomarker measurements
only in patients undergoing surgery, thereby excluding those receiving primary endocrine
therapy (most likely ER positive cases).
The pattern of biomarkers showing a consistent rise, a consistent fall, an initial rise then
a fall or vice versa is in keeping with the available literature [9] and also the age stratified
pattern of ER, PgR, HER2, luminal and basal cytokeratins, Ki67 and EGFR is consistent with
the existing literature [2,9,10,15]. However, the pattern of markers with age stratification
according to their ER status has never been reported before. In addition, our study includes
a large panel of biomarkers with long term clinical outcomes making our study novel.
The pattern of p53 appeared in contrast to the results of other studies [2,9,10,15] where
there was a consistent reduction in positive expression; however, the results of our study
support the concept of reduction in the DNA repairing ability of the cells with advancing
age. In our study we looked at the protein expression of p53 which if present suggests the
presence of the mutant p53 gene. Within our data the pattern of p53 was different in ER
positive and ER negative groups, with decreasing numbers of positive p53 cases in the ER
negative subgroup and increasing numbers in the ER positive subgroup, where there is
again a possibility that the ER positive tumours might have pathological relation to somatic
p53 mutations in older women as a result of long standing oestrogen stimulation for cell
division. Nevertheless, in future, in vitro or cell line studies will be required to analyse the
role of p53 in breast cancer development and progression in older women.
Overall the pattern of biological markers showed three different groups based on
their biological characteristics: (i) “≤40 years” where there was low ER, PgR, luminal
cytokeratins, bcl2 and high Ki67, HER2 and p53 expression; (ii) exactly the opposite pattern
was seen in older women “>70 years”, and (iii) the third group “between 40 and 70 years”,
suggesting a “transition” stage. The age-related biological pattern is in keeping with the
general impression of aggressive tumour biology in very young patients and less aggressive
biology in older women. Another interesting point worth noting about the pattern of age
groups is that patients <40 years are expected to be pre-menopausal. The older age group
(>70 years) are invariably post-menopausal while those between 40 and 70 should include
pre-, peri- and early post-menopausal women. This pattern supports the hypothesis that
circulating oestrogens may play a key role in determining the biology of breast cancer.
In addition, when closely looking at the carcinogenesis which involves proto-oncogenes
(which promote cell division) and tumour suppressor genes (which suppress cell division),
the younger age group theoretically appears to be linked with proto-oncogenes while the
older age with faulty suppressor mechanism. However, little is known about the precise
relationship between carcinogenesis and age.
The clinical outcome data reported in our study suggests that older women achieved
better survival as compared to the younger population where there was poor metastasis-
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free and breast cancer specific survival. This is in line with the aggressive tumour biology
in younger patients (Table 1). There is an interesting finding of significantly better clinical
outcome among older women again suggesting a favourable biology. There was no
significant difference in the survival of patients with ER negative tumours based on age
though younger patients received more aggressive therapy (i.e., adjuvant chemotherapy
was given to the majority of patients of <40 years while none of the older (>70 years) patients
received it (Table 3). Among patients with ER positive tumours, the use of chemotherapy
was reduced with advancing age as only two patients in the older age group received
such treatment, while endocrine therapy was widely used: over 64% of older women (>70)
received such treatment. The treatment pattern is in line with the existing literature which
suggests a less aggressive treatment pattern in older women. Thus, the difference in the
clinical outcome with better survival in older women appears to be influenced by less
aggressive biology.
Our study is strengthened by incorporating a large sample size with long term follow-
up including all age groups. Such a large dataset comparing biological characteristics
across all age groups from a single centre following the same methods is reported for the
first time. The tumour samples were prospectively collected and tissue micro-arrays were
constructed with biomarker measurements using a centralised and standardised protocol
from a single laboratory. However, the study has the limitation of not including needle
core biopsy specimens thus a considerable number of the older women who received
non-surgical therapy were excluded giving a potential bias towards having proportionally
more ER negative tumours in the older age group.
4. Materials and Methods
4.1. Patients
This study included women with early-stage operable breast cancer (clinically T0–2N0-
1M0) undergoing primary surgery without any prior intervention, from two series of well
characterised patients managed at a dedicated facility following the same management
protocol at any given time, with good quality surgical resection samples available for
tissue micro-array (TMA) construction. The women ≤70 years of age were from the
Nottingham primary breast cancer series (n = 1808) [16] and women ≥70 years from the
Nottingham elderly primary breast cancer series (n = 575) [17]. For this study patients
were grouped in decades according to their age at diagnosis, i.e., ≤30, 31–40, 41–50, 51–60,
61–70, 71–80 and ≥80 years. The study was approved by the Research Ethics Committee
at the Nottingham City Hospital under ethical approval number C2020313. The tumour
samples were collected historically before the Human Tissue Act came in. The Research
Ethics Committee considered that patient consents were deemed not necessary.
4.2. Tumour Analysis
Tissue microarrays were constructed from formalin-fixed paraffin-embedded surgical
specimens [18]. Briefly, Haematoxylin and Eosin was used to identify the most representa-
tive part of the tumour, and 0.6 mm-diameter cores of the representative part of the tumour
blocks were implanted in the TMA blocks using Beecher’s manual tissue microarrayer
(MP06 Beecher Instruments Inc., Sun Prarie, WI, USA). One most representative core was
taken for each TMA block. Biological analysis of the tumours was carried out using indirect
immunohistochemistry (IHC) by StreptAvidin Biotin Complex and EnVision methods
as described [19]. Immunohistochemical scoring for tissue staining was done by using
McCarty’s immunohistochemical scoring (H-score) (range 0–300) [20] and the percentage of
positive cells was counted. The H-scoring system considers both number of cells showing
staining and intensity of the staining in each cell. X-tile Bio-informatics software was used
to define cut-offs to define positive expression of the biomarkers [21]. Cut-off values of the
protein expression was previously defined [7] and Table S1 is attached.
Immunohistochemical analysis of the TMAs was carried out for a panel of 16 biomark-
ers, including hormone receptors (ER and PgR), HER2, Ki67, luminal (CK7/8, CK18,CK19,
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MUC1, E-cadherin and bcl2 and HER4) and basal (BRCA1, CK5/6, CK14, CK17 and
p53) markers.
Given the distinct differences in the clinical behaviour between ER positive and ER
negative tumours, both groups were compared in terms of their biological pattern and
clinical outcome.
4.3. Clinical Outcome
The clinical outcome of the patients was analysed in terms of breast cancer specific
survival and metastases free survival, defined as the time duration from date of diagnosis
till death and confirmation of distant metastases, respectively.
4.4. Statistical analysis
The data was analysed using Statistical Package for Social Sciences (SPSS version 18.0,
Chicago, IL, USA). The Kruskal–Wallis test was applied to evaluate the groups to see if
there were any dominant patterns. This was followed by the application of Mann–Whitney
U test to locate the difference, which was further confirmed by Chi-square test. Survival
analysis was done by using Kaplan–Meier methods with application of Log-rank and
generalised Wilcoxon tests as appropriate. A p-value <0.05 was considered significant.
5. Conclusions
In conclusion, we confirm that the biology of breast cancer alters with age, with
a gradual rise of good prognostic markers illustrating a characteristic pattern of three
groups with cut-off age points at 40 years and 70 years. The clinical outcome was better
among older patients in general, those with ER positive tumours having significantly
better survival as compared to their younger counterparts within same age group while
there was no significant difference in the clinical outcome in ER negative subgroups. The
treatment pattern showed more aggressive adjuvant therapy given in younger patients
when compared to the older patients. The study thus suggests a less aggressive tumour
biology with advancing age resulting in better survival. Further studies are required to
understand cellular mechanisms and age induced changes in the intracellular environment
leading to the development and/or progression of breast cancer in order to optimise the
management of women with different tumour phenotypes.
Supplementary Materials: The following are available online at https://www.mdpi.com/2072
-6694/13/6/1417/s1, Figure S1: (a) Breast cancer specific survival—comparison of age groups
<40, 41–70 years and >70 years, (b) Breast cancer specific survival Oestrogen receptor positive—
comparison of age groups <40, 41–70 years and >70 years, (c) Breast cancer specific survival in
Oestrogen receptor negative—comparison of age groups <40, 41–70 years and >70 years, (d) Breast
cancer specific survival <40 years—comparison of oestrogen negative and oestrogen receptor positive
groups, (e) Breast cancer specific survival 41–70 years—comparison of oestrogen negative and oestro-
gen receptor positive groups, (f) Breast cancer specific survival >70 years—comparison of oestrogen
negative and oestrogen receptor positive groups, g. Local recurrence free survival—comparison of
age groups <40, 41–70 years and >70 years, (h) Local recurrence free survival <40 years—comparison
of oestrogen negative and oestrogen receptor positive groups, (i) Local recurrence free survival
41–70 years—comparison of oestrogen negative and oestrogen receptor positive groups, (j) Local
recurrence free survival >70 years—comparison of oestrogen negative and oestrogen receptor positive
groups, (k) Local recurrence free survival Oestrogen receptor positive—comparison of age groups
<40, 41–70 years and >70 years, (l) Local recurrence free survival Oestrogen receptor negative—
comparison of age groups <40, 41–70 years and >70 years, (m) Regional recurrence free survival
Oestrogen receptor negative—comparison of age groups <40, 41–70 years and >70 years, (n) Regional
recurrence free survival Oestrogen receptor positive—comparison of age groups <40, 41–70 years and
>70 years, (o) Metastases free survival Oestrogen receptor negative—comparison of age groups <40,
41–70 years and >70 years, (p) Metastases free survival Oestrogen receptor positive—comparison of
age groups <40, 41–70 years and >70 years; Table S1: Immunostaining cut-offs and cellular localization.
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